Delayed Treatment of Ebola Virus Infection with Plant-Derived Monoclonal Antibodies Provides Protection in Rhesus Macaques
Abstract
Filovirus infections can cause a severe and often fatal disease in humans and nonhuman primates, including great apes. Here, three anti-Ebola virus mouse/human chimeric mAbs (c13C6, h-13F6, and c6D8) were produced in Chinese hamster ovary and in whole plant (Nicotiana benthamiana) cells. In pilot experiments testing a mixture of the three mAbs (MB-003), we found that MB-003 produced in both manufacturing systems protected rhesus macaques fromlethal challenge when administered 1 h postinfection. In a pivotal followup experiment, we found significant protection (P < 0.05) whenMB- 003 treatment began 24 or 48 h postinfection (four of six survived vs. zero of two controls). In all experiments, surviving animals that received MB-003 experienced little to no viremia and had few, if any of the clinical symptoms observed in the controls. The results represent successful postexposure in vivo efficacy by a mAb mixture and suggest that this immunoprotectant should be further pursued as a postexposure and potential therapeutic for Ebola virus exposure.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 15, 2012
- Accession Number
- ADA570060
Entities
People
- Ashley K. Johnson
- Barry Bratcher
- Cara Working
- Do Kim
- Ernie Hiatt
- Gene G. Olinger Jr.
- James Pettitt
- Josh Morton
- Ognian Bohorov
- Steven D. Hume
Organizations
- United States Army Medical Research Institute of Infectious Diseases